The feasibility of adding both the multidrug resistance modulator cyclosporin (CsA) and granulocyte colony-stimulating factor (G-CSF) to a standard salvage regimen of idarubicin (IDA) and cytarabine was evaluated in patients with resistant or relapsed acute myeloid leukemia and myelodysplastic syn- 
Introduction
Since the introduction of anthracyclines in the treatment of acute myeloid leukemia (AML) the prognosis of patients with AML has improved markedly. 1 From pharmacokinetic studies we learned that the optimal balance between toxicity and efficacy was obtained after continuous infusion. 2, 3 New anthracyclines like the analogue 4-demethoxydaunorubicin (idarubicin, IDA) appeared more effective. IDA has a minor alteration at position 4 of the chromophore ring compared to daunorubicin (dauno), which results in a prolonged half-life of the hydroxy derivate. In vivo IDA is rapidly metabolized to idarubicinol (ida-ol). The cytotoxic activity of ida-ol is comparable to its parent compound in contrast to daunorubicinol. [4] [5] [6] Despite these and other chemotherapeutic developments, treatment regimens fail in 20-30% in AML because of primary or acquired drug resistance. Several studies showed that Pglycoprotein, encoded by the multidrug resistance-1 (MDR-1) gene is expressed on leukemic blasts of newly diagnosed AML patients and correlates with clinical resistance. Increased Pgp expression has also been reported after exposure to anthracyclines. [7] [8] [9] [10] [11] [12] The clinical importance of other resistance phenotypes such as the MDR related protein-1 (MRP1) and lung related protein (LRP) is currently being investigated. 13 and MRP1 both function as efflux pumps, lowering the intracellular anthracycline concentration and consequently the efficacy of the drug. 19, 20 Several agents, including calcium channel antagonists and cyclosporine (CsA), are shown to be effective modulators of Pgp and MRP1 efflux in vitro. [21] [22] [23] [24] [25] Studies on the role of Pgp and MRP1 expression in IDA and ida-ol efficacy showed controversial results. The direct effect of Pgp on cellular pharmacokinetics of IDA are negligible. Some in vitro studies show that IDA is MRP1-dependent. 26, 27 Little is known about the effects of MDR mechanisms on the accumulation of the active metabolite ida-ol. 28, 29 We have reported that both normal and leukemic blast cells with a relatively high Pgp expression are predominantly noncycling cells and less sensitive to anthracycline toxicity. Triggering these cells into proliferation by hematopoietic growth factors (HGFs) increased in vitro anthracycline sensitivity by downregulation of Pgp expression. 30, 31 Priming of leukemic blasts with HGFs also increases cytarabine (Ara-C) efficacy. 32 In vivo the role of proliferation induction of leukemic blasts by HGFs might be an alternative, specific and less toxic way to circumvent drug resistance. [32] [33] [34] Despite several strategies designed to overcome MDP, little improvement has been made in the treatment of relapsed or resistant AML. Specific blockade of one resistance mechanism, may select or induce an escape by other resistance mechanisms. In the present study the feasibility of the addition of CsA and granulocyte colony-stimulating factor (G-CSF) to a standard salvage regimen of IDA and Ara-C was evaluated in an attempt to overcome both Pgp and MRP1 in AML. The feasibility was studied in a group of patients with poor prognosis: patients with either early relapsed or refractory AML or myelodysplastic syndrome (MDS). Pgp and MRP1 expression, the pharmacology of IDA and ida-ol in plasma and in leukemic blasts, as well as cell cycle kinetics were evaluated.
Patients and methods

Patients
Patients with primary resistant AML/MDS or relapsed within 6 months after an anthracycline containing regimen were eligible, provided their age was between 15 and 65 years and their WHO performance status 2 or less. Patients positive for hepatitis B surface antigen, or a known history of hepatitis C or HIV infection, impairment of hepatic function (ASAT or ALAT) as defined as Ͼ2.5 times the institutional upper limit (IUL) were excluded. Patients were to have an adequate renal function defined as serum creatinine р175 g/l, a normal cardiac function and no severe rhythm abnormalities. Patients who received prior treatment with MDR modulators during chemotherapy and patients with severe neurological or psychiatric illness or other malignancies were excluded. Refractoriness to HLA matched platelet substitution, hypersensitivity 81 to ingredients of study medication, hyperviscosity due to hyperleukocytosis or uncontrolled infections were other exclusion criteria. During and after the treatment, medication known to affect CsA metabolism and other MDR blocking agents were not allowed. The protocol received approval from the Institutional Ethics Board and written informed consent was obtained from all patients.
Dosing schedule and study design
This is a prospective nonrandomized single arm pilot study. Patients received treatment with IDA (12 mg/m 2 on day 1, 3 and 5) given as a 24 h continuous intravenous (i.v.) infusion through a central venous catheter, combined with Ara-C (two times per day 500 mg/m 2 on days 1-5) given as a 2 h i.v. infusion. G-CSF (5-10 g/kg, subcutanously) was started 2 days prior to the first dose of IDA and continued until bone marrow recovery. In case the white blood count (WBC) rose to levels above 50 × 10 9 /l, G-CSF administration was interrupted until the WBC was Ͻ50 × 10 9 /l. A CsA loading dose (6 mg/kg/i.v. over 2 h on day 1), before the start of IDA was followed by continuous CsA infusion (16 mg/kg/days on days 1-6). An effective CsA level for complete MDR1 blockade (ranges from 500 to 2000 ng/ml required) was expected with this dose. 35 In case ASAT or ALAT or creatinine levels increased to 2.5-fold the baseline values, CsA dosage was reduced to 50%. In case liver or renal function further deteriorated, CsA was stopped. Dose of CsA was not modified in case of hyperbilirubinemia. The study had to be stopped and modified if more than three out of seven patients suffered untreatable toxicity (grade 3 or 4) or died as a result of the therapy. This stop criterion corresponds with an incidence of 12.2-73.8 (95% confidence limit). The subsequent patients were to receive a reduced dose IDA of 9 mg/m 2 . The same stopping rules were applied to this modified regimen. After a partial response to the first course, a second course was considered. After obtaining complete remission, a consolidation course was planned, which was identical to the remission induction course. Replacement of the salvage or consolidation treatment with an allogeneic bone marrow transplantation was allowed. Patients were excluded from further protocol treatment if no CR or PR was achieved or if irreversible or untreatable toxicity occurred during or after the treatment (eg liver and renal functions Ͼ2.5 times IU/l or serum bilirubin Ͼ3 times IU/l, even after a 3-week delay) before the next cycle. Any medical problem prior, during and after the therapy, such as bleeding, infection and metabolic abnormalities was analyzed carefully and treated accordingly.
Evaluation of therapy and toxicity
Complete remission (CR), partial response (PR), relapse and treatment failure including resistant leukemia and early death or leukemic regrowth were defined according to standard criteria. 36 Treatment-related toxicity was monitored daily and graded according to the National Cancer Institute toxicity scale (CTC-NCIC).
Clinical monitoring and sample collection
Daily physical examination and registration of vital signs was required. Complete blood cell count with differential, blood Leukemia chemistry, and electrolytes were determined daily for the first 7 days and at least three times a week thereafter. Bone marrow examination was performed before therapy and after bone marrow recovery. Samples for IDA, and ida-ol were collected from the peripheral blood daily the first 8 days and on days 10, 12 and 15. Samples for CsA were collected on days 3, 5, 8 and 10. Samples for IDA and ida-ol monitoring were also collected from three patients who received the standard salvage protocol with IDA 12 mg/m 2 , Ara-C, but no CsA and G-CSF.
Isolation of cells
Mononuclear cells from bone marrow or peripheral blood samples were isolated by Ficoll 1.077 (Sigma Chemical, St Louis, MO, USA) and cryopreserved at a concentration of 0.2 to 0.4 × 10 6 cells/ml in liquid nitrogen. Prior to the experiments, cells were thawed as described before, 31 resuspended in Iscove's medium (Life Technologies, Paisley, UK) with 10% v/v fetal calf serum (FCS, Hyclone, Logan, UT, USA) and stained with monoclonal antibodies (MoAbs), rhodamine or propidium iodide (PI).
Flow cytometry
A Coulter Epics Elite Flow cytometer (Coulter, Miami, FL, USA) was used for the measurement of PI (610 nm long pass filter) and rhodamine fluorescence (515 nm long pass filter), as well as fluorescein isothiocyanate (FITC) and phycoerythrin (PE) labeled monoclonal antibodies (MoAb). Gating on forward and right angle scatter was used to exclude dead cells and debris. Blasts ware gated on forward scatter. The area and peak of the red fluorescence signal was recorded in list mode. The ratio area:peak was used to discriminate artifacts due to doublets of diploid cells.
Pgp and MRP1 expression on blast cells Rhodamine efflux assay:
The rhodamine efflux assay is a sensitive method to detect Pgp and/or MRP1 expression. 37, 38 The cells were incubated (200 000 cells/ml) in Iscove's medium at a final rhodamine concentration (Rh123, Sigma Chemical) of 0.1 g/ml for 60 min, 37°C. After centrifugation, the cells were resuspended for 2 h, 37°C in Iscove's medium with or without 2 g/ml (2 M) CsA or 25 M verapamil (Knoll AG, Ludwigshaven, Germany). Cellular rhodamine fluorescence was measured by flow cytometry. 39 The rhodamine efflux ratio is defined as the fluorescence intensity of the mean logarithmic cellular rhodamine content in the presence of verapamil or CsA divided by the mean logarithmic fluorescence intensity in the absence of verapamil (or CsA). A rhodamine dull subpopulation (%) is considered MDR positive when it becomes bright in the presence of verapamil or CsA. MDR expression was considered positive if the efflux ratio was Ͼ1.5, or a rhodamine subpopulation of Ͼ5% was detected.
MoAb staining:
The MoAb's UIC2-PE (Immunotechnology, Marseille, France) was used for Pgp staining. MRP1 expression was detected by labeling with MRPr1 (Immunotechnology). Cells were fixed with 100% acetone (5 min, RT). 40 The cellular fluorescence ratio is the mean logarithmic fluorescence for antibody (UIC2-PE or MRPm6-FITC) divided by the mean logarithmic fluorescence for control. Pgp and MRP1 expression was considered positive if the cellular fluorescence ratio was Ͼ1.5, or if a Pgp or MRP1 subpopulation of Ͼ5% was detected.
Measurement of cell cycle distribution
PI (Calbiochem, San Diego, CA, USA) was used to measure DNA content. The cells were lysed in 300 l of ice cold hypotonic PI solution (20 g/ml PI, 0.1% w/v tri-sodium citrate dihydrate (Merck, Darmstadt, Germany), 10% v/v RNA-se solution (RNA-se A, Sigma Chemical,) 1 mg/ml in G-PBS and 0.1% v/v Triton X-100 in dH 2 O. Cells were kept on ice overnight and analyzed for DNA content by flow cytometry.
In vitro proliferation induction of blasts
To study the effect of growth factors on the cell cycle of the leukemic cells 1 × 10 6 cells/ml were dissolved in Iscove's medium, with 20% v/v FCS with 20 ng/ml G-CSF (Amgen, Thousand Oaks, CA USA) or the combination of 20 ng/ml G-CSF, 50 ng/ml interleukin (IL)-3 (Sandoz, Basel, Switzerland) and 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) (Sandoz) at 37°C for 48 h.
Idarubicin and idarubicinol pharmacokinetics
After collection of the blood samples on ice, plasma was immediately separated from the cells by centrifugation (4°C, 1500 g, 5 min). The pellet was lysed twice with cold ammonium chloride and resuspended in phosphate buffered saline (PBS). The recovery of the leukocytes after lysis was 80-95%. Plasma and cell suspensions were stored at −20°C until analysis.
A capillary electrophoresis method described by Hempel et al, 41 with minor modifications, was used to determine plasma and cellular IDA and ida-ol concentrations. 200 l plasma, 100 l Tris buffer (pH 9.0), l internal standard (daunorubicin 40 ng/ml in acetonitrile) and 1 ml chloroform were vortexed (1 min) and centrifuged (1500 g, 5 min). 900 l of the organic phase was transferred into an Eppendorf vial and dried under a gentle stream of nitrogen at room temperature for 12-16 h. The residue was resuspended in 50 l acetonitrile/water (95/5) and injected into the capillary by electrokinetic injection. A P/ACE 5000 capillary electrophoresis apparate (Beckman, Fullerton, CA, USA) equipped with an 488 nm argon ion laser and with a fused silica capillary 310 (L eff ) × 0.075 mm (ID) was used. Separation was carried out with an applied voltage of 532 V/cm (25 kV) cathode on detector side. Between runs, the capillary was rinsed with sodium hydroxide 0.1 N for 1 min and the running buffer for 2 min. Quality control and calibration samples were prepared by diluting standard solutions with blank plasma or cell suspensions to final concentrations of 500, 250, 100, 50, 25, 10, 5 and 0 ng/ml.
The area under the curve (AUC) was calculated for IDA and ida-ol plasma and cellular concentrations in the period days 1-5. Subsequently, a plasma and cellular ratio of the ida-ol vs IDA (R ida-ol/IDA) AUCs was calculated.
Cyclosporin A
Samples for CsA levels were collected on days 3, 5, 8 and 10. Plasma CsA concentration was determined with the TD x /TD x FL x cyclosporin monoclonal whole blood assay. Reagents were obtained from Abbot Laboratories Diagnostic Division (Chicago, IL, USA)
Statistical analysis
The Mann-Whitney test was applied for statistic analysis of the results.
Results
Patients
Between May 1997 and January 1998, seven patients aged 20-58 years, with refractory (n = 2) or early relapsed (n = 5) AML or MDS were included. Previous treatment consisted of 1-3 chemotherapy courses according to the protocols AML 10 EORTC (06931) or CRIANT EORTC (06961). Patient characteristics and prior therapy are listed in Table 1 . Two patients had primary failure after one and two courses, respectively. Three patients had relapsed after a remission of 1 to 4 months. Two patients had a failure after treatment with a second-line therapy at first relapse.
Toxicity and response to treatment
The first three patients were treated with IDA 12 mg/m 2 (group A) ( Table 2 ). All developed severe mucositis grade III (CTC-NCIC), requiring treatment with morphine i.v. for 6 to 31 days. One patient died during hypoplasia. In accordance with the stop criteria the subsequent four patients received IDA 9 mg/m 2 (group B). Overall, grade III or IV gastrointestinal (diarrhea or mucositis) toxicity was observed in six patients, cardiovascular toxicity (edema) in two patients. G-CSF had to be stopped in one case, because of severe (grade IV) bone pain. Four patients complained of headache (grade II or III) during the administration of the CsA, but these complaints were acceptable after symptomatic pain relief or administration of propranolol. All patients developed grade III or IV infections during neutropenia. Serum bilirubin levels increased during CsA administration but normalized after stopping the CsA. No important increase of the SGOT and SGPT was observed (Table 3) .
One patient developed skin lesions identical to lesions observed at first presentation of the disease (patient No. 7). Morphologic examination of the skin showed a leucocytoclastic vasculitis. During treatment with CsA, this patient showed an increase of serum creatinine levels, irreversible after lowering and subsequently stopping the CsA administration on day 4. Renal failure developed and the patient had to be treated with hemodialysis. CsA toxicity superimposed on renal vasculitis is held responsible for renal failure. Subsequently this patient developed grade IV neurological cortical toxicity (epileptic insults and somnolence). Pneumonia complicated the clinical course and the patient finally died of multi-organ failure (MOF).
One patient showed a PR after one course and was consolidated with an allogeneic bone marrow transplantation. She is 83 Partial response (PR) was defined as CR except the bone marrow contains Ͼ5 and Ͻ25% blasts or Ͻ5% blasts in the presence of Auer rods. Treatment failure (TF) was defined as resistant leukemia or death during the 7 days of induction treatment or death during bone marrow hypoplasia. Leukemic regrowth was diagnosed if after initial clearing of circulating blast cells, a rapid increase of these blasts to Ͼ1 × 10 9 /l occurred more than 15 days after start of the course. in continued CR. Three patients showed leukemic regrowth and three patients died during hypoplasia.
Pharmacology of idarubicin and idarubicinol
A representative example (pA) of plasma and cellular IDA and ida-ol concentrations during treatment with IDA 12 mg/m 2 Leukemia and CsA (group A) is shown in Figure 1 . Both IDA and idaol cellular concentrations were Ͼ100-fold above the plasma concentrations. The concentration of ida-ol was higher than that of IDA in both plasma and cells. Figure 1 also shows the plasma and cellular IDA and ida-ol concentrations in a control patient (pC) treated with IDA 12 mg/m 2 without CsA. Plasma concentrations of IDA and even more pronounced ida-ol were lower in the absence of CsA. Also the cellular ida-ol concen- The mean AUCs of IDA and ida-ol were highest in group A, 31.3 and 81.1 ng/ml × days in plasma and 4974 and 7616 ng/ml × days in cells. In group B (IDA 9 mg/m 2 with CsA) AUC values for IDA and ida-ol were 19.4 and 64.7 ng/ml × days in plasma and 4404 and 7220.7 ng/ml × days in cells. Without CsA, IDA and ida-ol showed the lowest AUC values, 18.8 and 29.9 ng/ml × days in plasma and 5839 and 3498 ng/ml × days in cells. The plasma AUCs of IDA and ida-ol of group A were significantly (P Ͻ 0.05) higher than those of controls. Reduction of the IDA from 12 to 9 mg/m 2 in the presence of CsA resulted in a lower plasma ida-ol, but still significantly higher (P Ͻ 0.05) than the plasma ida-ol AUC values of controls. The differences in plasma IDA AUCs between group B and controls were not significant. These data demonstrate that the plasma IDA and ida-ol AUCs increase in the presence of CsA were even more pronounced for ida-ol than IDA.
Cellular IDA AUCs were comparable after IDA 9 or 12 mg/m 2 /day and with or without CsA. Cellular ida-ol AUCs were also comparable in group A and B, despite differences in plasma ida-ol. The cellular ida-ol of both group A and B were significantly higher (P Ͻ 0.05) than those of controls.
Cellular IDA and ida-ol accumulation as the net result of uptake and efflux correlated to the plasma concentrations with a coefficient between the cellular and the plasma AUCs of IDA and ida-ol of 0.3 and 0.6, respectively.
The mean ratio of AUCs of ida-ol vs IDA (R ida-ol/IDA) was 2.6 in plasma and 1.5 in cells for group A, 4.4 in plasma and 1.8 in cells for group B and 1.6 in plasma and 0.6 in cells for group C. The mean R ida-ol/IDA in plasma of group A and B were significantly higher (P Ͻ 0.05) than that of controls.
Pharmacology of cyclosporin A
CsA had to be stopped after 4 days in one patient (No. 7), because of renal toxicity. Levels of у1500 ng/ml were reached in all seven patients (Table 2 ) with a mean value of 1960 on day 5.
MDR expression
The leukemic blasts showed similar rhodamine efflux with verapamil and CsA: two of seven samples showed a substantial rhodamine dull subpopulation and an efflux ratio Ͼ1.5 (Table 4) . To discriminate between Pgp and MRP1 expression staining with specific MoAbs was also done. Six samples were Pgp-positive and none of the samples was MRPI-positive. Two MDR positive samples in the rhodamine efflux assay were also Pgp-positive by MoAb staining, while four MoAb-Pgp-positive samples did not show a substantial rhodamine dull subpopulation.
Cell cycle analysis and in vitro proliferation with HGFs
DNA analysis of leukemic blasts showed almost exclusively noncycling cells before therapy in patient 3 and 4 (2 and 0.5%, respectively), which could be triggered to proliferate in vitro by growth factors to 20 and 15%, respectively. In patients 2, 5, 6 and 7, 16-23% of the cells were in S/G + M phase, not enhanced by in vitro growth factor stimulation. In patient 1 with 12% of the cells in S/G + M an increase to 18% was seen. In all cases that growth factors stimulated the cycling status of the cells in vitro the combination of G-CSF, GM-CSF and IL-3 was more effective than G-CSF alone.
Figure 2
Plasma and cellular AUCs (ng/ml × days) of all patients treated with IDA 12 mg/m 2 and CsA and (group A), patients treated with IDA 9 mg/m 2 and CsA and (group B) and control patients treated with the standard salvage regimen IDA 12 mg/m 2 without CsA (group C). -: Mean AUC of group A, B and C.
Discussion
The salvage chemotherapy regimen with IDA 12 mg/m 2 on days 1, 3 and 5 and intermediate-dose Ara-C combined with CsA as MDR modulator and G-CSF for proliferation induction appeared too toxic even after 25% IDA dose reduction. All The mean log rhodamine fluorescence with verapamil or CsA divided by the mean log rhodamine fluorescence without verapamil or CsA. MDR expression was considered positive if the efflux ratio was Ͼ1.5, or a rhodamine subpopulation of Ͼ5% was detected. b The mean log fluorescence for antibody (UIC2-PE or MRPrl-GITC) divided by the mean log for control. Pgp and MRP1 expression was considered positive if the fluorescence ratio was Ͼ1.5, or if a Pgp or MRP1 subpopulation of Ͼ5% was measured.
Leukemia patients developed grade III or IV toxicity. Six out of seven patients had severe mucositis or diarrhea. Only one patient responded and remained relapse-free after allogeneic bone marrow transplantation. It needs to be emphasized that the patients included had a very poor prognosis. All patients were pretreated with one to three courses intensive chemotherapy.
Where they reached complete remission, the remission duration was less than 5 months. Two patients failed on secondline chemotherapy.
The regimen was based on previous trials in AML showing IDA to give better results than daunorubicin. A randomized study in AML performed by the Memorial Sloan Kettering Cancer Center, comparing IDA to dauno in combination with standard dose Ara-C, resulted in a significantly higher CR rate (80% vs 58%), 42 which was confirmed in other studies. 43, 44 Salvage therapy with 7 days intermediate-dose Ara-C in combination with IDA (12 mg/m 2 ) on days 1, 3 and 5 in patients with AML or MDS relapsed or refractory after one or two induction courses (EORTC-LCG study 06901) appeared both feasible and effective. 36 Eleven out of 21 patients (52%) entered a complete remission with a median remission duration of 8.5 months. This salvage regimen was modified with the MDR modulator CsA and G-CSF.
Yahanda et al 45 and List et al 35 reported in phase I and II clinical trials that the effective levels of the MDR modulator CsA were achievable with acceptable and transient toxicity. The overall response rate in 42 evaluable patients with poor risk AML was 69% (62% CR). It remains unclear whether the reported clinical response is due to pharmacokinetic changes (higher or prolonged doxorubicin levels) or specific Pgp blockade or a combination. In pediatric patients with poor risk AML, toxicity of CsA was acceptable and response rates of MDR1 positive and negative patients were comparable. 46 Tallman et al 47 reported no clinical benefit from CsA in association with Pgp expression in poor risk AML patients. Currently PSC 833 is tested in a phase III trial with poor risk AML. Wattel et al 48 first demonstrated in a randomized trial some clinical benefit from the modulator quinine in MDS.
The MDR reversal agents may result in inhibition of the anthracycline clearance due to modulation of Pgp efflux in kidney or biliary tract. At the time of starting this study no data were available on changes in IDA and/or ida-ol clearance in vivo in the presence of CsA. IDA is thought to reduce the induction of Pgp and in vitro data show that it is less dependent on Pgp efflux compared with daunorubicin, but sensitive to MRP1 modulation. 19, 29 For this reason we did not start with a reduced dose of IDA. Our results show that the plasma concentration of both IDA and ida-ol was significantly (P Ͻ 0.05) increased in the presence of CsA. The increase in plasma AUCs explains the high and undesired toxicity. Since the pharmacokinetic changes are clearly more pronounced for ida-ol than for IDA, the high toxicity observed is thought to result mainly from ida-ol. Recently, Damiani et al 49 also reported an increased AUC of plasma IDA by CsA due to increased half-life. No data were given on ida-ol plasma concentrations and of IDA and ida-ol cellular concentrations. Pea et al 50 analyzed plasma IDA and ida-ol concentrations in the presence of CsA and concluded that CsA significantly increased systemic body exposure to both IDA and ida-ol.
The importance of this study in our opinion is the measurement of both plasma and cellular IDA and ida-ol concentrations. As expected, there was a strong correlation between plasma and cellular concentrations for both IDA and ida-ol. Interestingly, cellular IDA concentrations were almost similar for IDA 9 or 12 mg/m 2 /day with or without CsA, suggesting saturation. Cellular ida-ol concentrations were comparable for IDA 9 or 12 mg/m 2 /day only in the presence of CsA, also suggesting saturation. In addition, the ratio of AUC of ida-ol/IDA in cells and plasma were Ͼ1 in all patients treated with CsA, in contrast with patients treated with IDA 12 mg/m 2 /day without CsA. These data support the hypothesis that CsA blocks specific efflux mechanisms like Pgp resulting in reduced cellular ida-ol clearance. Moreover, our data suggest that ida-ol is more MDR-dependent than IDA. In vitro research with AML blasts by Schroder et al 51 supports this clinical observation. We measured cellular IDA and ida-ol concentrations in the overall cell population. Effects might be more outspoken in the MDR-positive subpopulation. The high GI toxicity can be explained by Pgp blocking on gastrointestinal (GI) epithelial cells. [52] [53] [54] Pgp and MRP expression on leukemic cells was studied by both a functional rhodamine efflux assay and staining with MoAbs. The rhodamine efflux assay with prolonged efflux (2 h) does not discriminate between Pgp and MRP1. 38 Only two samples were MDR-positive in the efflux assay. Staining with MoAbs showed six Pgp-positive and no MRP1-positive samples. Previous reports also showed conflicting results between the functional assay and direct labeling with MoAbs. 9, 11, 55, 56 All patients included in this trial were pretreated with an anthracycline containing regimen: six patients were treated with IDA and one patient with mitoxantrone. Currently, no conclusive data are available on Pgp and MRP1 expression on blasts of clinically resistant AML patients after pretreatment with IDA. Analysis of the two patients who were Pgp-positive by both methods (MoAb and efflux assay) did not show a higher cellular IDA or ida-ol concentration in the presence of CsA than the other patients.
G-CSF was added before and during the chemotherapy to trigger leukemic blasts into proliferation. Leukemic blasts heterogeneously express receptors for hematopoietic growth factors (HGFs) varying in number, type and affinity. 57 Drach et al 58 reported that IL-3 and G-CSF induced downregulation of MDR expression in vivo. We have previously demonstrated that both normal and leukemia blasts with a high Pgp expression are noncycling cells and that in vitro proliferation induction of these cells resulted in Pgp downregulation. 31 Multiple studies showed that HGFs, particularly IL-3, GM-CSF and G-CSF can stimulate proliferation of leukemic blasts in vitro. [59] [60] [61] [62] Van der Lely et al 32 showed that induction of proliferation in AML blasts in vitro chemosensitivity, but highly variable in subsets of leukemic blasts and for the HGF applied. Preliminary data from clinical trials suggest better chemotherapy results after priming with HGFs. 63, 64 In this study, cell cycle analysis showed that a substantial number of cells were in G0/G1 phase before treatment and HGF stimulation in vitro increased the percentage cycling cells in four of seven patients. Since Pgp is highly expressed by the noncycling more primitive normal hematopoietic progenitors, 39 priming with HGFs and CsA may also sensitize these cells to chemotherapeutic effects and probably results in a prolonged bone marrow aplasia. No increase in the duration of aplasia due to HGFs before and after chemotherapy has been reported until now. In vivo, HGFs have also been administered successfully after the chemotherapy in order to accelerate hematopoietic recovery. 34, 65 Therefore G-CSF was continued after the chemotherapy until bone marrow repopulation.
This study shows that pharmacokinetics of both IDA and ida-ol are substantially modulated by CsA modulation. This resulted in a too toxic regimen, even after 25% dose reduction. Other MDR modulators like PSC 833 have shown a similar effect on plasma pharmacokinetics. 66, 67 The modulating effect of CsA in vivo was mainly due to changes in the plasma concentration, but also cellular ida-ol concentrations were increased by CsA. We conclude that efficacy of IDA and especially its metabolite ida-ol might be improved by specific MDR modulators, but the increased toxicity will be the limiting factor of this approach. Monitoring of plasma and cellular concentrations are warranted in future protocols.
